Enlicitide

DRUG11 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HealthyHepatic ImpairmentHepatic InsufficiencyHypercholesterolemiaHyperlipidemiaRenal Impairment

Phase 1

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

CompletedNCT06575959

Merck Sharp & Dohme LLCHepatic Impairment, Hepatic Insufficiency

Start: 2024-09-20End: 2025-05-08Updated: 2025-05-28

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

CompletedNCT06597760

Merck Sharp & Dohme LLCHealthy

Start: 2024-10-07End: 2024-11-15Updated: 2024-11-29

A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

CompletedNCT06609512

Merck Sharp & Dohme LLCHealthy

Start: 2024-10-21End: 2025-01-31Updated: 2025-02-07

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

CompletedNCT06643377

Merck Sharp & Dohme LLCHealthy, Renal Impairment

Start: 2024-11-22End: 2025-06-25Updated: 2025-07-23

A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)

CompletedNCT06719544

Merck Sharp & Dohme LLCHealthy

Start: 2025-01-02End: 2025-02-06Updated: 2025-02-17

A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

CompletedNCT06880874

Merck Sharp & Dohme LLCHealthy

Start: 2025-04-02End: 2025-05-31Updated: 2025-06-15

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

CompletedNCT07044479

Merck Sharp & Dohme LLCHealthy

Start: 2025-07-03End: 2025-08-28Updated: 2025-09-03

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

Active, not recruitingNCT07300280

Merck Sharp & Dohme LLCHealthy

Start: 2025-12-29End: 2026-07-22Target: 60Updated: 2026-03-18

A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

Active, not recruitingNCT07481708

Merck Sharp & Dohme LLCHealthy

Start: 2026-03-23End: 2026-05-25Target: 30Updated: 2026-04-03

Phase 3

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

CompletedNCT06450366

Merck Sharp & Dohme LLCHypercholesterolemia

Start: 2024-07-08End: 2025-03-28Updated: 2026-03-27

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

RecruitingNCT07216482

Merck Sharp & Dohme LLCHyperlipidemia

Start: 2025-11-11End: 2027-03-01Target: 975Updated: 2026-04-01